AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation. About AbCellera B.
- 12/20/2023
|
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
- One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others.
- 12/16/2023
|
Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform
- AbCellera Biologics is a biotech company using AI-powered platforms to discover and analyze target-specific antibodies. The company emphasizes partnerships to expedite drug development and has two drugs set for IND approval in 2025. AbCellera has a strong financial position and is trading at a relatively low cash multiple, making it an attractive investment in biotech.
- 12/07/2023
|
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023.
- 11/16/2023
|
AbCellera Biologics Inc. (ABCL) Q3 2023 Earnings Call Transcript
- AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Participants Allison Bratzel - Piper Sandler Robyn Karnauskas - Truist Andrea Tan - Goldman Sachs Stephen Willey - Stifel Puneet Souda - Leerink Partners Steven Mah - Cowen Malcolm Hoffman - BMO Operator Good afternoon, and welcome to AbCellera's Third Quarter 2023 Business Update Conference Call. My name is Kate, and I will facilitate the audio portion of today's interactive broadcast.
- 11/02/2023
|
New Strong Buy Stocks for October 26th
- GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.
- 10/26/2023
|
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023.
- 10/11/2023
|
3 AI Stocks You'll Regret Not Buying Soon
- Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatment, creating big opportunities for these top AI stocks to invest in. At the moment, new drug development has a ridiculous fail rate of 90%, according to the National Institutes of Health.
- 08/08/2023
|
AbCellera Biologics Inc. (ABCL) Q2 2023 Earnings Call Transcript
- AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - Chief Executive Officer & President Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldman Sachs Antonia Borovina - Bloom Burton Steven Mah - Cowen Stephen Willey - Stifel Malcolm Hoffman - BMO Gaurav Goparaju - Berenberg Operator Good afternoon, and thank you, and welcome to AbCellera's Second Quarter 2023 Business Update Conference Call. My name is Jason, and I will be the facilitator for the audio portion of today's interactive broadcast.
- 08/03/2023
|
Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 242.1% in AbCellera Biologics Inc. (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/25/2023
|
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom
- AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery.
- 07/08/2023
|
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023.
- 05/29/2023
|
7 Growth Stocks That Could Double Your Money in 2023
- While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks.
- 05/14/2023
|
AbCellera Biologics: TCE Program Alone Could Be Worth More Than The Current Market Cap
- AbCellera reported results from the first quarter on May 4th. To put it bluntly, the actual earnings print means next to nothing in this name at this stage. The company had a very busy and productive quarter under the surface, reporting progress on multiple fronts, specifically the TCE program (T-cell engager).
- 05/06/2023
|
AbCellera Biologics Inc. (ABCL) Q1 2023 Earnings Call Transcript
- AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldman Sachs Antonia Borovina - Bloom Burton Stephen Willey - Stifel Nishant Gandhi - Truist Gaurav Goparaju - Berenberg Puneet Souda - SVB Securities Malcolm Hoffman - BMO Steven Mah - Cowen Operator Good afternoon. And welcome to AbCellera's First Quarter 2023 Business Update Conference Call.
- 05/04/2023
|
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates
- AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.54 per share a year ago.
- 05/04/2023
|
7 Stocks Under $10 That Analysts Love
- Generally speaking, you get what you pay for, which on paper doesn't bode well for these bargain stocks under $10. Nevertheless, with thousands upon thousands of tradable securities available to public investors, at least a few will go unnoticed.
- 04/24/2023
|
7 Best Stocks Under $10 to Buy in April
- Although financial advisors often direct you to established, reliable enterprises, in some cases, you can find compelling ideas among the best stocks under $10. To be fair, such companies tend to be more volatile than your standard blue-chip fare.
- 04/11/2023
|
AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 2023 Bloom Burton & Co.
- 04/11/2023
|
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
- While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.
- 04/05/2023
|
Confounded's Complete All-Weather Portfolio Revealed
- Most readers follow my work for the extensive writing I have done referencing my aggressive growth portfolio. However, the vast majority of my net worth is held in my all-weather portfolio. In this article, I would like to draw back the curtain on my main, all-weather portfolio, where roughly 80% of my assets reside.
- 04/01/2023
|
7 Stocks to Bet On if You Want to Be Richer Than Elon Musk
- If you aspire to one day topple entrepreneurial genius Elon Musk on the net wealth rankings through the equities market exclusively, you're obviously going to need to conduct heavy research on the stocks that can make you rich. However, you also want to be smart about this.
- 03/22/2023
|
AbCellera Biologics Inc (ABCL) Q4 2022 Earnings Call Transcript
- AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fauth - Credit Suisse Andrea Tan - Goldman Sachs Gary Nachman - BMO Robyn Karnauskas - Truist Gaurav Goparaju - Berenberg Antonia Borovina - Bloom Burton Operator Good afternoon. And welcome to AbCellera's Full-Year 2022 Business Update Conference Call.
- 02/21/2023
|
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
- AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/21/2023
|
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
- You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.
- 02/02/2023
|
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
- VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).
- 02/01/2023
|
Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?
- Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.
- 01/24/2023
|
AbCellera Biologics: My Updated Current Valuation Estimate
- In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. In the last year, many of my inputs I previously used have changed, given the greater transparency of the company throughout 2022. Some for the better, some for the worse.
- 01/05/2023
|
10 Potential 10x Return Stocks For The Next 10 Years
- While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.
- 01/04/2023
|
AbCellera Biologics: Q3 Commentary - Moving Up The Value Stack
- AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines. The company, in the days before the release, indicated that Regeneron has advanced its first GCPR target into preclinical development, further validating its platform.
- 11/09/2022
|
AbCellera Biologics Inc (ABCL) Q3 2022 Earnings Call Transcript
- AbCellera Biologics Inc (NASDAQ:ABCL ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer and President Andrew Booth - Chief Financial Officer Conference Call Participants Do Kim - Piper Sandler Gaurav Goparaju - Berenberg Capital Markets Stephen Willey - Stifel Financial Corp. Gary Nachman - BMO Capital Markets Antonia Borovina - Bloom Burton Operator Good afternoon. And welcome to AbCellera's Third Quarter 2022 Business Update Conference Call.
- 11/08/2022
|
AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates
- AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2022
|
AbCellera to Present at Upcoming Investor Conferences in November
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November
- 11/04/2022
|
AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth
- AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/01/2022
|
AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
- AbCellera Biologics reported Q2 numbers that were not all that impressive; however, the news of the commercialization agreement its partner Lilly inked has driven shares to near YTD highs. The commercialization plan looks to provide AbCellera with continued non-dilutive funding to further build its now $1 billion cash war chest.
- 08/14/2022
|
AbCellera Reports Q2 2022 Business Results
- AbCellera (ABCL) recently announced its Q2 2022 business results. These are the details.
- 08/10/2022
|
Why AbCellera Biologics Rallied as Much as 24% on Wednesday
- The contract drug developer's stock is finally shaking off the froth of its initial public offering.
- 08/10/2022
|
AbCellera Biologics Inc. (ABCL) CEO Dr. Carl Hansen on Q2 2022 Results - Earnings Call Transcript
- AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and CEO Andrew Booth - CFO Conference Call Participants Tiago Fauth - Credit Suisse Puneet Souda - SVB Securities Stephen Willey - Stifel Gary Nachman - BMO Capital Markets Do Kim - Piper Sandler Antonia Borovina - Bloom Burton Operator Good afternoon and welcome to AbCellera Second Quarter 2022 Business Update and Conference Call. My name is Libya and I'll facilitate the audio portion of today's indirect broadcast.
- 08/10/2022
|
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
- AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2022
|
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
- 07/12/2022
|
AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?
- AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 06/20/2022
|
AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
- AbCellera stock has continued to struggle of late given the absolutely terrible sentiment in the biotech market, however the company's actual business is thriving under the surface. In the Q1 earnings call, the company highlighted both the internally developed T-Cell engager platform, along with the Empirico deal which provides the option to co-invest in programs.
- 06/06/2022
|
Why AbCellera Biologics Is 10% Lower Today
- The company has a plan for life after COVID-19, though it pales in comparison.
- 05/11/2022
|
AbCellera Biologics Inc. (ABCL) CEO Dr. Carl Hansen on Q1 2022 Results - Earnings Call Transcript
- AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2022 Results Conference Call May 10, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fauth - Credit Suisse Puneet Souda - SVB Securities Stephen Willey - Stifel Gary Nachman - BMO Capital Markets Do Kim - Piper Sandler Antonia Borovina - Bloom Burton Operator Good afternoon and welcome to AbCellera First Quarter 2022 Financial Results Conference Call. My name is Amber and I'll facilitate the audio portion of today's indirect broadcast.
- 05/10/2022
|
AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates
- AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2022
|
3 Biotech Stocks Under $10 to Add to Your Buy List
- These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on InvestorPlace.
- 04/26/2022
|
AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
- AbCellera, the stock, has had a woeful two plus years as a public company; however, AbCellera the business is performing brilliantly. The company recently announced an internally developed T-Cell engager program that it is looking to partner, likely at attractive terms for AbCellera, giving the company another avenue to monetization.
- 04/22/2022
|
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
- 04/12/2022
|
Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q4 2021 Earnings Call Transcript
- Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q4 2021 Earnings Call Transcript
- 02/24/2022
|
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
- 02/11/2022
|
AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
- AbCellera announced on Thursday Feb 10th a supply deal with the US government and Lilly for Bebtelovimab, the AbCellera developed pan COVID variant antibody treatment.
- 02/11/2022
|
AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
- AbCellera has been pummeled in the market this year, dropping like a stone to the current price of just over $14 a share. I believe this is a huge mistake. AbCellera currently has 131 programs with royalty agreements under contract and that number continues to grow fast.
- 12/05/2021
|
Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q3 2021 Results - Earnings Call Transcript
- Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Why AbCellera Biologics Stock Sank 21.6% in October
- The biotech is now down roughly 56% across 2021's trading.
- 11/04/2021
|
AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy
- AbCellera shares have been rocked by news of Merck's "COVID pill" treatment, sending shares down 25% from recent highs. In September, AbCellera's current antibody therapy was put back into use after an FDA pause, giving the company back a key revenue source
- 10/18/2021
|
Why AbCellera Biologics Stock Jumped 19.4% Last Month
- Despite last month's gains, the biotech stock is now down roughly 61% year to date.
- 10/07/2021
|
AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies
- AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.
- 09/23/2021
|
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
- VANCOUVER, British Columbia and SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.
- 09/22/2021
|
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
- 09/21/2021
|
ABCL Stock: Why It Increased Today
- The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) increased by over 16% pre-market. This is why it happened.
- 09/17/2021
|
AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody
- The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SARS-CoV-2 infection. Bamlanivimab emerged from the collaboration between Eli Lilly And Co (NYSE: LLY) and AbCellera Biologics Inc (NASDAQ: ABCL).
- 09/17/2021
|
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--EUA of Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
- 09/16/2021
|
Why AbCellera Biologics Stock Jumped 7% on Wednesday
- The company's drug-development technology is starting to attract attention.
- 09/15/2021
|
AbCellera Shares Are Moving Higher On Licensing Pact With Moderna
- AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for mRNA medicines. The collaboration will leverage AbCellera's AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.
- 09/15/2021
|
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
- VANCOUVER--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
- 09/10/2021
|
Here's Why AbCellera Biologics Stock Gained 10.6% Last Month
- Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading.
- 09/04/2021
|
AbCellera Biologics: I Was Wrong
- AbCellera reported Q2 results on 08/12/21 which were well received by the market, sending shares up 15%. A remark by the CEO in the conference call, however, has me quite concerned. The company since IPO has indicated that royalties negotiated are between single digits and low double digits, allowing the impression to set that the average is somewhere in the 8-12% range.
- 08/20/2021
|
Why AbCellera Biologics Stock Was Up More Than 17% on Friday
- The biopharma company's second quarter was better than expected. The future looks pretty bright, too.
- 08/13/2021
|
AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q2 2021 Results - Earnings Call Transcript
- AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
AbCellera Reports Q2 2021 Business Results
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q2 2021 Business Results
- 08/12/2021
|
AbCellera Biologics: A Buy At Current Prices
- AbCellera Biologics: A Buy At Current Prices
- 08/06/2021
|
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
- HOUSTON & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
- 08/03/2021
|
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. The live webcast of the earnings conference call will be available through a link that will be posted on AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call. A
- 07/22/2021
|
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
- VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have entered into separate share purchase agreements with experienced institutional investors (the “Buyers”), pursuant to which the Buyers purchased an aggregate 11,900,000 common share
- 06/10/2021
|
AbCellera Biologics: My Highest Conviction Pick, With The Longest Potential Payoff
- I recommended AbCellera on March 8, 2021, and so far the stock has gone pretty much nowhere. However, I am as bullish as ever. Immediate catalysts are lacking, but that does not preclude you from accumulating this stock at a reasonable valuation before the fireworks start.
- 05/31/2021
|
AbCellera (ABCL) Stock: Over 7% Increase Explanation
- The stock price of AbCellera (Nasdaq: ABCL) increased by over 7% during intraday trading this morning. This is why it happened.
- 05/17/2021
|
CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q1 2021 Business Results
- 05/14/2021
|
Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug
- AbCellera stock tumbled Friday, despite in-line royalties for its Lilly-partnered Covid drug. Here's why the stock toppled.
- 05/14/2021
|
AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call Transcript
- AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
AbCellera-Lilly Partnered Second COVID-19 Antibody Enters Human Trials
- AbCellera Biologics Inc (NASDAQ: ABCL) has announced that a second antibody from its collaboration with Eli Lilly and Co (NYSE: LLY), LY-CoV1404, has entered clinical trials in patients with mild-to-moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and together with other monoclonal antibodies.
- 05/04/2021
|
Published Peer-Reviewed Data Demonstrate Bamlanivimab's High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--Published data show high potency of bamlanivimab against SARS-CoV-2 and support its clinical effectiveness to treat and prevent COVID-19.
- 04/05/2021
|
AbCellera, Gilead Ink New Multi-Target Antibody Discovery Collaboration
- AbCellera Biologics Inc (NASDAQ: ABCL) has announced agreements to expand its collaboration with Gilead Sciences Inc (NASDAQ: GILD), including a multi-year, multi-target antibody discovery collaboration. Under the agreements' financial terms, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties.
- 04/01/2021
|
ABCL Stock Price Increased Over 10% Pre-Market: Why It Happened
- The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) has increased by over 10% pre-market. This is why it happened.
- 03/30/2021
|
AbCellera Biologics' (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call Transcript
- AbCellera Biologics' (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call Transcript
- 03/29/2021
|
AbCellera Biologics: A Compounding Machine In Biotech Clothing
- AbCellera Biologics is a little followed and largely uncovered company. What it is building however is known all throughout the biotech and pharma industries. With the likes of Bill Gates, Peter Thiel and DARPA as key backers, AbCellera is quietly creating a call option on vast swaths of new and emerging biotech.
- 03/08/2021
|
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
- 03/05/2021
|
AbCellera to Present at the SVB Leerink Global Healthcare Conference
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.
- 02/17/2021
|
Why AzurRx BioPharma, Usana Health Are Moving Today
- Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. The company also announced a $150 million buyback.
- 02/10/2021
|
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #EUA--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
- 02/09/2021
|
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
- 01/27/2021
|
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
- 01/26/2021
|
F-star Therapeutics: New Biologics Platform For Immunotherapy
- F-star Therapeutics: New Biologics Platform For Immunotherapy
- 01/21/2021
|
AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology
- VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology.
- 01/19/2021
|
AbCellera CEO on effectiveness of Covid-19 anitbody treatment
- AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments.
- 01/13/2021
|
Andreas Halvorsen Jumps Into 2 New Biotech Companies
- Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a Premium feature.
- 12/22/2020
|
AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
- VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
- 12/15/2020
|
IPO Stock Madness Moves to Biotech as AbCellera, Certara Soar
- Hot initial public offerings aren't just for technology companies.
- 12/11/2020
|
Certara, AbCellera Lead Flurry of Health-Care IPOs
- Four companies increased the size of their deals.
- 12/11/2020
|
AbCellera Announces Pricing of Initial Public Offering
- VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.
- 12/10/2020
|
AbCellera Biologics Proposes $357 Million IPO Terms
- AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide.
- 12/07/2020
|
